Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.
/Merck%20%26%20Co%20Inc%20HQ%20-by%20Sundry%20Photography%20via%20iStock.jpg)
Merck & Co. is all set to announce its fiscal second-quarter results this month, and analysts are projecting a notable triple-digit earnings growth.
/Hologic%2C%20Inc_%20%20magnified%20-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Hologic is expected to report its third-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.
/Teleflex%20Incorporated%20sign%20at%20office-by%20Tada%20Images%20via%20Shutterstock.jpg)
Teleflex will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line dip.
/Stryker%20Corp_%20HQ%20sign%20-by%20Sundry%20Photography%20via%20Shutterstock.jpg)
Stryker will unveil its Q2 earnings later this month, and analysts project a single-digit profit growth.
/Pfizer%20Inc_%20logo%20on%20iPad-by%20Koshiro%20K%20via%20Shutterstock.jpg)
As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.
/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
DexCom is gearing up to announce its second-quarter results this month, and analysts are anticipating a double-digit increase in the company’s bottom-line figure.
/Boston%20Scientific%20Corp_%20logo%20on%20iPad-%20by%20Kate%20Krav-Rude%20via%20Shutterstock.jpg)
Boston Scientific is expected to report its second-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.
/Baxter%20International%20Inc_%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Baxter International is poised to release its second-quarter results this month, and analysts are projecting a double-digit earnings growth.
/Abbvie%20Inc%20billboard%20-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.